Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment.
Gabriele MelegariEnrico GiulianiChiara DallaiLucia VeronesiElisabetta BertelliniSuela OsmenajAlberto BarbieriPublished in: Journal of personalized medicine (2021)
Our observational data follow the most relevant largest trial. Patients treated with tocilizumab had lower rates of new-onset symptoms later COVID-19 ICU hospitalizations. As reported by recent medical literature, the presence of these symptoms suggests that a follow-up program for these types of patients could be useful.
Keyphrases
- end stage renal disease
- coronavirus disease
- ejection fraction
- sars cov
- rheumatoid arthritis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- healthcare
- systematic review
- clinical trial
- machine learning
- intensive care unit
- study protocol
- depressive symptoms
- patient reported
- physical activity
- artificial intelligence
- systemic lupus erythematosus
- big data
- acute respiratory distress syndrome